REGENXBIO INC (RGNX)
US75901B1070 - Common Stock
We assign a fundamental rating of 3 out of 10 to RGNX. RGNX was compared to 587 industry peers in the Biotechnology industry. While RGNX seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, RGNX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year RGNX has reported negative net income.
RGNX had a negative operating cash flow in the past year.
In the past 5 years RGNX reported 4 times negative net income.
RGNX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of RGNX (-41.36%) is comparable to the rest of the industry.
RGNX has a Return On Equity of -66.61%. This is comparable to the rest of the industry: RGNX outperforms 57.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.36% | ||
| ROE | -66.61% | ||
| ROIC | N/A |
ROA(3y)-22.69%
ROA(5y)-20.56%
ROE(3y)-40.7%
ROE(5y)-34.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RGNX's Gross Margin of 56.86% is amongst the best of the industry. RGNX outperforms 80.51% of its industry peers.
RGNX's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for RGNX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.86% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.58%
GM growth 5Y-9.28%
2. Health
2.1 Basic Checks
RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RGNX has been increased compared to 1 year ago.
Compared to 5 years ago, RGNX has more shares outstanding
RGNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
RGNX has an Altman-Z score of -0.41. This is a bad value and indicates that RGNX is not financially healthy and even has some risk of bankruptcy.
RGNX has a Altman-Z score (-0.41) which is comparable to the rest of the industry.
There is no outstanding debt for RGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.41 |
ROIC/WACCN/A
WACC9.09%
2.3 Liquidity
RGNX has a Current Ratio of 3.59. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.59, RGNX is doing worse than 60.51% of the companies in the same industry.
RGNX has a Quick Ratio of 3.59. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
RGNX has a Quick ratio of 3.59. This is comparable to the rest of the industry: RGNX outperforms 40.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.59 | ||
| Quick Ratio | 3.59 |
3. Growth
3.1 Past
RGNX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.57%.
Looking at the last year, RGNX shows a very negative growth in Revenue. The Revenue has decreased by -20.79% in the last year.
The Revenue for RGNX have been decreasing by -16.21% on average. This is quite bad
EPS 1Y (TTM)6.57%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q13.07%
Revenue 1Y (TTM)-20.79%
Revenue growth 3Y-16.43%
Revenue growth 5Y-16.21%
Revenue growth Q2Q-18.21%
3.2 Future
RGNX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.25% yearly.
RGNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 57.09% yearly.
EPS Next Y23.43%
EPS Next 2Y27.65%
EPS Next 3Y20.76%
EPS Next 5Y15.25%
Revenue Next Year30.69%
Revenue Next 2Y51.51%
Revenue Next 3Y42.88%
Revenue Next 5Y57.09%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
RGNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RGNX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RGNX's earnings are expected to grow with 20.76% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.65%
EPS Next 3Y20.76%
5. Dividend
5.1 Amount
RGNX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REGENXBIO INC
NASDAQ:RGNX (5/16/2024, 9:59:36 AM)
15.98
-0.25 (-1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap783.66M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.36% | ||
| ROE | -66.61% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 56.86% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.14
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.59 | ||
| Quick Ratio | 3.59 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)6.57%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y23.43%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-20.79%
Revenue growth 3Y-16.43%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y